What Is Melanotan II? Mechanism, Research & Safety

Melanotan II (MT-II) is a synthetic, cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that has circulated in research and gray-market circles for decades because of its pronounced effects on skin pigmentation. Unlike many peptides covered on this site, MT-II is not an approved medicine anywhere, and the published literature on it is a mix of pharmacology papers, case reports describing adverse events, and a small number of registered clinical trials exploring narrower, physician-supervised indications. This article summarizes what the research literature actually documents — mechanism, findings, and safety signals — and is intended strictly for research and educational purposes only.

What Is Melanotan II?

Melanotan II is a lab-synthesized cyclic heptapeptide designed in the 1980s at the University of Arizona as part of a research program investigating melanocortin peptides for skin-cancer prevention and sunless-tanning applications. It is structurally related to alpha-MSH, the endogenous hormone that signals melanocytes to produce melanin, but MT-II was engineered for greater metabolic stability and a longer duration of action than the native hormone.

Critically, MT-II is a non-selective melanocortin receptor agonist: it activates MC1R, MC3R, MC4R, and MC5R, rather than acting narrowly on the skin-pigmentation receptor alone. That lack of selectivity is the central fact that shapes almost everything else in this article — both MT-II’s pigmentation effects and its broader, less desirable physiological effects trace back to this multi-receptor activity. A more selective derivative, afamelanotide (marketed as Scenesse), targets MC1R specifically and holds regulatory approval in some jurisdictions for a narrow indication (erythropoietic protoporphyria); MT-II itself has no approved medical indication anywhere.

Mechanism of Action

Non-selective melanocortin receptor activation

Melanocortin receptors are G protein-coupled receptors distributed across different tissues: MC1R predominates in skin melanocytes, MC3R and MC4R are concentrated in the hypothalamus and central nervous system, and MC5R is found in exocrine tissue. A 2023 pharmacology review by Mun, Kim, and Shin in International Journal of Molecular Sciences describes how MC1R activation triggers a cAMP-mediated signaling cascade that upregulates microphthalmia-associated transcription factor (MITF), in turn increasing expression of tyrosinase and related enzymes that drive melanin production (Mun et al., 2023). Because MT-II activates this pathway alongside MC3R/MC4R/MC5R pathways, its pharmacological profile differs meaningfully from receptor-selective analogs.

MC1R and melanogenesis

Activation of MC1R on melanocytes shifts pigment production toward eumelanin (the darker brown-black pigment), which is the mechanistic basis for MT-II’s tanning effect independent of ultraviolet exposure. This is also why the compound has attracted research interest as a UV-independent approach to studying pigmentation biology and photoprotection pathways, even though MT-II itself remains unapproved for any such use.

MC4R and off-target effects

MC4R is heavily involved in central appetite regulation and sexual-arousal pathways. The same 2023 review notes that MT-II analogs produce measurable effects on sexual behavior in animal models, including induction of penile erections in male rats and increased sexual receptivity in female rats — effects attributable to MC4R (and related receptor) activation rather than to melanogenesis (Mun et al., 2023). This receptor cross-talk is the pharmacological reason MT-II is associated with appetite suppression and spontaneous sexual arousal in addition to its pigmentation effects — a pattern distinct from more receptor-selective melanocortin peptides.

Research Background and Key Findings

The broader melanocortin-1 receptor literature has matured considerably in recent years. A 2025 overview by Böhm and colleagues in the Journal of the European Academy of Dermatology and Venereology synthesizes benefits and risks of chronic MC1R activation, noting that MC1R signaling supports UV-protective pigmentation, DNA-repair processes, and control of aberrant cell growth, but explicitly cautions that receptor activation does not prevent melanoma — particularly in individuals with existing risk factors — and that regular skin examination remains essential for anyone with elevated melanoma risk (Böhm et al., 2025).

Because MT-II has circulated for years as an unregulated, self-administered substance outside clinical settings, much of the human safety data comes from individual case reports rather than controlled trials:

• Sivyer (2012), writing in Dermatology Practical & Conceptual, documented a 16-year-old patient with FAMMM syndrome (a hereditary condition involving atypical moles and elevated melanoma risk) who self-administered Melanotan injections alongside sunbed use and developed diffuse skin darkening and an enlarging groin lesion that histopathology confirmed as a dysplastic compound nevus (Sivyer, 2012).
• A 2026 case report by Bonchev in Life documented a previously undescribed adverse effect: symmetric brown pigmentation of the attached gingiva and buccal mucosa in a 42-year-old man following 64 days of self-administered MT-II injections, with partial regression of the oral pigmentation over the three months following discontinuation (Bonchev, 2026).

Both reports illustrate a consistent theme in the MT-II literature: melanocortin receptor activation is not confined to the skin patients intend to tan — it can affect pigment-producing cells throughout the body, including oral mucosa and pre-existing melanocytic lesions, in ways that are unpredictable outside supervised clinical protocols.

Separately, melanocortin agonism continues to be explored in formally regulated research settings for indications unrelated to cosmetic tanning. A registered trial (ClinicalTrials.gov identifier NCT07437560) is evaluating investigational Melanotan II as an adjunct to narrow-band UVB (NB-UVB) phototherapy for repigmentation in adults with stable nonsegmental vitiligo — a strictly supervised, protocol-driven context that is fundamentally different from unsupervised self-administration and does not extend to any other use of the peptide.

Taken together, the literature supports MT-II as a mechanistically well-characterized but clinically unapproved compound: its melanogenic effects are pharmacologically plausible and consistent with MC1R biology, while its non-selective receptor activity and case-report safety signals — particularly around melanocytic lesions — are the primary reasons it remains outside approved medical use.

Forms, Reconstitution & Handling

In research contexts, MT-II is typically supplied as a lyophilized (freeze-dried) powder in sealed vials, such as the 10mg format. Like most lyophilized peptides, it requires reconstitution with an appropriate diluent before it can be used in any laboratory protocol, and the accuracy of that reconstitution step directly affects the reliability of any downstream measurement or observation.

Our general peptide reconstitution guide walks through calculating dilution volumes, mixing technique, and vial-labeling practices that apply broadly across lyophilized research peptides, including melanocortin analogs like MT-II. For laboratories handling any injectable-format research material, our injection best-practices guide covers general aseptic technique, equipment handling, and documentation practices relevant to controlled research settings.

Research Considerations

Any research protocol involving MT-II should account for considerations that are specific to its pharmacology rather than generic to peptides broadly:

• Non-selectivity of effect — Because MT-II activates multiple melanocortin receptor subtypes simultaneously, experimental designs and observational endpoints should account for effects beyond pigmentation, including appetite-related and behavioral measures in animal models.
• Baseline dermatologic documentation — Given the case-report literature on nevus and mole changes, any protocol involving live models with pre-existing pigmented lesions should include baseline dermatologic photography and documentation before any exposure.
• Model and history screening — The FAMMM-syndrome case report underscores that individuals or models with a personal or family history of atypical nevi or melanoma represent a materially different risk category and should be excluded from unsupervised or exploratory protocols.
• Batch and lot documentation — As with any research peptide, consistent labeling, storage logs, and batch records support reproducibility.

These are general laboratory-practice notes, not instructions for human use, and do not substitute for institutional ethics or biosafety review.

Storage & Stability

Lyophilized MT-II is generally handled using the same storage principles that apply to other peptide powders:

• Lyophilized (powder) form: Store frozen (around −20°C), protected from light and moisture, in a tightly sealed vial until reconstitution.
• Reconstituted solution: Refrigerate (2–8°C) and use within the timeframe appropriate for the specific preparation; avoid repeated freeze–thaw cycles, which can degrade peptide integrity.
• Light sensitivity: As with many peptides, minimizing light exposure during both powder and solution storage is standard laboratory practice.

Consult our peptide reconstitution guide for more detail on general handling and storage practices for lyophilized research peptides.

Safety, Legality & Research Disclaimers

Melanotan II is not an approved drug for the treatment, cure, or prevention of any disease or cosmetic condition, and nothing in this article should be interpreted as medical advice or a recommendation for human use. Because MT-II has circulated for years outside regulated pharmaceutical channels, there is no formal pharmacovigilance system tracking adverse events in real-world users, and the true incidence of serious outcomes — including melanoma and dysplastic nevi — associated with unsupervised use is not established in the literature.

Reported adverse effects in the published case-report and pharmacology literature include nausea, facial flushing, spontaneous sexual arousal or erections, changes to the color, size, or shape of existing moles and nevi, and — as detailed above — pigmentation changes in oral mucosa. Individuals or research models with a personal or family history of melanoma, dysplastic nevi, or a high total nevus count represent an elevated-risk category based on the case-report literature discussed above.

Anyone conducting research involving MT-II is responsible for confirming its current legal status in their jurisdiction and for complying with their institution’s ethics, biosafety, and research-governance requirements. Regulatory status varies by country, changes over time, and should always be verified independently before beginning any work. Material intended for laboratory research should never be applied, injected, or otherwise administered to humans or animals outside of a properly approved research protocol.

Frequently Asked Questions

What is Melanotan II, in simple terms? Melanotan II is a synthetic, cyclic analog of alpha-MSH that non-selectively activates melanocortin receptors, most notably MC1R (skin pigmentation) and MC4R (appetite and sexual-arousal pathways in the brain). It is not an approved medicine.

How is Melanotan II different from Melanotan I or afamelanotide? Melanotan I and afamelanotide are more MC1R-selective analogs, meaning they activate the skin-pigmentation receptor at concentrations well below those needed to meaningfully engage MC3R/MC4R/MC5R. MT-II’s lack of selectivity is why it is associated with a broader range of off-target effects, including appetite and sexual-arousal changes.

Why do case reports mention changes to moles? Because MC1R activation is not confined to the areas of skin a person intends to tan, it can also affect melanocytes within existing nevi. Published case reports describe darkening, growth, and — in at least one instance involving a patient with a hereditary melanoma-risk syndrome — a dysplastic nevus emerging during Melanotan use (Sivyer, 2012).

Is Melanotan II being studied for any approved medical use? Not currently. A registered trial is evaluating investigational use alongside NB-UVB phototherapy for vitiligo repigmentation under supervised clinical conditions, but this is a distinct, protocol-governed research context and does not represent an approved indication or a basis for self-administration.

How is Melanotan II typically supplied for research? As a lyophilized powder in sealed vials, commonly available in a 10mg format, requiring careful reconstitution before use in any laboratory protocol.

Is Melanotan II legal? Its regulatory status varies by jurisdiction and is unsettled in many places precisely because it lacks approval as a medicine. Researchers are responsible for verifying current local regulations before beginning any work.

References

1. Böhm, M., Robert, C., Malhotra, S., Clément, K., & Farooqi, S. (2025). An overview of benefits and risks of chronic melanocortin-1 receptor activation. Journal of the European Academy of Dermatology and Venereology, 39(1), 39–51.
2. Mun, Y., Kim, W., & Shin, D. (2023). Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. International Journal of Molecular Sciences, 24(15), 12152.
3. Sivyer, G. W. (2012). Changes of Melanocytic Lesions Induced by Melanotan Injections and Sun Bed Use in a Teenage Patient with FAMMM Syndrome. Dermatology Practical & Conceptual, 2(2), 26–29.
4. Bonchev, A. (2026). Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report. Life, 16(2), 265.
5. ClinicalTrials.gov. Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo. Identifier NCT07437560.

Disclaimer: This information is for educational and research purposes only. Peptides are research chemicals not intended for human consumption.